Rising Cancer Prevalence Driving Growth In The Next-Generation Sequencing Data Analysis Market Driving Market Acceleration in the Next-Generation Sequencing Data Analysis Industry, 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Next-Generation Sequencing Data Analysis Market Size By 2025?
The market size for next-generation sequencing data analysis has experienced immense growth recently. Its valuation is projected to rise from $1.21 billion in 2024 to $1.48 billion in 2025, with a compound annual growth rate (CAGR) of 22.0%. Factors such as its rising use for the detection of pathogens, utilization in both veterinary diagnostics and research, its growing use in identifying uncommon genetic diseases, the intensified attention towards microbiome research, and the increasing application of NGS in pharmacogenomics have powered its growth in the historian era.

How Big Is the Next-Generation Sequencing Data Analysis Market Size Expected to Grow by 2029?
The market size of next-generation sequencing data analysis is predicted to soar in the upcoming years, with an anticipated valuation of $3.24 billion in 2029, showcasing a compound annual growth rate (CAGR) of 21.7%. This forecasted growth is driven by increasing efforts to incorporate genomics in healthcare, professional healthcare education, focus on public health surveillance, decreased sequencing costs, and a heightened interest in studies related to epigenetics. Among the prominent trends anticipated during the forecast span, we can highlight innovation in single-cell sequencing, automation in the processing of NGS data, progression in NGS data visualization tools, adoption of blockchain technology, and advancements in hybrid sequencing techniques.

View the full report here:
https://www.thebusinessresearchcompany.com/report/next-generation-sequencing-data-analysis-global-market-report

Which Key Market Drivers Powering Next-Generation Sequencing Data Analysis Market Expansion and Growth?
The escalating prevalence of cancer is anticipated to drive the expansion of the next-generation sequencing data analysis market in the future. Cancer, defined as a cluster of diseases marked by the uncontrolled proliferation and dispersion of irregular cells in the human body, can culminate in severe health issues or mortality if left untreated. Unhealthy lifestyle behaviors, such as smoking, heavy drinking, and diets filled with processed foods while lacking fruits and vegetables, can considerably escalate cancer risk. By facilitating the precise detection of genetic mutations, next-generation sequencing data analysis aids cancer treatment. This can result in personalized therapies and the development of more efficacious treatment plans customized to the distinct genetic makeup of an individual's cancer. For example, in February 2024, the World Health Organization, an intergovernmental body headquartered in Switzerland, projected that by 2050, new cancer cases will surpass 35 million, signifying a 77% rise from a projected 20 million cases in 2022. Thus, the rising prevalence of cancer is propelling the growth of the next-generation sequencing data analysis market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19614&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Next-Generation Sequencing Data Analysis Market?
In the next-generation sequencing data analysis market, major firms are concentrating their efforts on the creation of advanced secondary analysis bioinformatics software. This software aims to expedite precise identification of genetic variants necessary for both research and clinical applications. The software processes and converts raw sequencing data from next-generation sequencing into understandable formats, like variant call files (VCF) - thus, making the complex analysis of NGS data simpler for research and clinical tasks. A fitting example of this is the QIAGEN CLC Genomics Workbench Premium, launched in January 2024 by QIAGEN Digital Insights, a US-based company. This software, equipped with LightSpeed technology, enhances next-generation sequencing processes for somatic cancer analysis and facilitates quick processing of whole genome sequencing samples. It has a capability of analyzing 34x human genomes in 25 minutes and 50x exomes in 90 seconds through efficient conversion of raw FASTQ data. The software proves to be an economical solution for high-output labs due to its low cost, with genomes priced at $1 and exomes at just a few cents, using cloud infrastructure. Operating on standard hardware or cloud platforms, the software boasts flexibility, impressive accuracy and is ideal for clinical use, all while keeping its carbon footprint as minimal as possible.

What Are the Emerging Segments in the Next-Generation Sequencing Data Analysis Market?
The next-generation sequencing data analysismarket covered in this report is segmented -

1) By Product: Services, Next-Generation Sequencing (NGS) Commercial Software
2) By Read Length: Short Read Sequencing, Long Read Sequencing, Very Long Read Sequencing
3) By Mode: In-House, Outsourced
4) By Workflow: Primary, Secondary, Tertiary
5) By End-User: Academic Research, Clinical Research, Hospitals And Clinics, Pharma And Biotech Entities, Other End-Users

Subsegments:
1) By Services: Data Analysis Services, Bioinformatics Services, Consulting Services, Sample Preparation Services, Training and Support Services
2) By Next-Generation Sequencing (NGS) Commercial Software: Data Management Software, Alignment Software, Variant Calling Software, Visualization Software, Pipeline Management Software, Specialized Analysis Software

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=19614&type=smp

Who Are the Global Leaders in the Next-Generation Sequencing Data Analysis Market?
Major companies operating in the next-generation sequencing data analysis market are Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., QIAGEN N.V., MedGenome Inc., Element Biosciences Inc., Seven Bridges Genomics Inc., Synthego Corp., Eurofins Genomics India Pvt. Ltd., Fabric Genomics Inc., Strand Life Sciences Pvt. Ltd., Admera Health LLC, Congenica Ltd., DNASTAR Inc., Golden Helix Inc., Geneious, SciGenom Labs Pvt. Ltd., Partek Incorporated, PathoQuest SAS, BioDatomics Inc., BGI Genomics Co. Ltd

Which are the Top Profitable Regional Markets for the Next-Generation Sequencing Data Analysis Industry?
North America was the largest region in the next-generation sequencing data analysis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation sequencing data analysis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19614

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe - +44 7882 955267,
Asia: +91 88972 63534,
Americas - +1 310-496-7795 or
Email: info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.